Acute Leukaemia
8
0
1
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (8)
A Study of BN104 in the Treatment of Acute Leukemia
A Safety and Efficacy Study of Eltrombopag in Subjects With AML
Natural Killer Cells in Acute Leukaemia and Myelodysplastic Syndrome
Targeted Radiotherapy in HSCT for Poor Risk Haematological Malignancy
Amplification and Selection of Antimicrobial Resistance in the Intestine
Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies
Palifermin After Haploidentical PBSCT
Leukemia Cell Cultures for Research of New Anti-Cancer Therapies